CD56bright natural killer (NK) cells: an important NK cell subset
Top Cited Papers
- 2 March 2009
- journal article
- review article
- Published by Wiley in Immunology
- Vol. 126 (4), 458-465
- https://doi.org/10.1111/j.1365-2567.2008.03027.x
Abstract
Human natural killer (NK) cells can be subdivided into different populations based on the relative expression of the surface markers CD16 and CD56. The two major subsets are CD56(bright) CD16(dim/) (-) and CD56(dim) CD16(+), respectively. In this review, we will focus on the CD56(bright) NK cell subset. These cells are numerically in the minority in peripheral blood but constitute the majority of NK cells in secondary lymphoid tissues. They are abundant cytokine producers but are only weakly cytotoxic before activation. Recent data suggest that under certain conditions, they have immunoregulatory properties, and that they are probably immediate precursors of CD56(dim) NK cells. CD56(bright) NK cell percentages are expanded or reduced in a certain number of diseases, but the significance of these variations is not yet clear.Keywords
This publication has 55 references indexed in Scilit:
- Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosusImmunology, 2008
- Human natural killer cellsBlood, 2008
- Interleukin‐21 differentially affects human natural killer cell subsetsImmunology, 2007
- Phenotypic Studies of Natural Killer Cell Subsets in Human Transporter Associated with Antigen Processing DeficiencyPLOS ONE, 2007
- Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-betaNeurological Sciences, 2007
- NK cell compartment in patients with coronary heart diseaseImmunity & Ageing, 2007
- TGFβ promotes conversion of CD16+peripheral blood NK cells into CD16−NK cells with similarities to decidual NK cellsProceedings of the National Academy of Sciences, 2007
- Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cellsJournal of Leukocyte Biology, 2006
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patientsEuropean Respiratory Journal, 2005